NCT01033123已完成2 期
A Phase 2, Multi-Center, Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- To evaluate the objective response rate (ORR) of gemcitabine/carboplatin in combination with BSI-201
研究概览
简要总结
The purpose of this study is to evaluate the effect of BSI-201 on the objective response rate in platinum-sensitive recurrent ovarian cancer patients receiving gemcitabine and carboplatin.
Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the laboratory, iniparib is a novel investigational anti-cancer agent that induces gamma-H2AX (a marker of DNA damage) in tumor cell lines, induces cell cycle arrest in the G2/M phase in tumor cell lines, and potentiates the cell cycle effects of DNA damaging modalities in tumor cell lines. Investigations into potential targets of iniparib and its metabolites are ongoing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age
- •Histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, or primary peritoneal carcinoma
- •Completion of only one previous course of chemotherapy which contained a platinum therapy, with sensitivity to that regimen. "Platinum-sensitivity" is defined by a relapse greater than 6 months after termination of platinum-based chemotherapy
- •Measurable disease, defined by at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded), and is ≥ 20 mm when measured by conventional techniques (palpation, plain x-ray, computed tomography [CT], or magnetic resonance imaging [MRI]) or ≥ 10 mm when measured by spiral CT
- •Adequate organ function defined as: absolute neutrophil count (ANC) ≥ 1,500/mm3, platelets ≥ 100,000/mm3, creatinine clearance > 50mL/min, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN; or < 5 x ULN in case of liver metastases); total bilirubin < 1.5 mg/dL
- •For women of child bearing potential, documented negative pregnancy test within two weeks of study entry and agreement to acceptable birth control during the duration of the study therapy
- •Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
- •Signed, institutional review board (IRB) approved written informed consent
排除标准
- •Concurrent invasive malignancy, not including:
- •Non-melanomatous skin cancer
- •In situ malignancies
- •Concurrent superficial endometrial carcinoma, if their endometrial carcinoma is superficial or invades less than 50% the thickness of the myometrium)
- •Low risk breast cancer (localized, non-inflammatory) treated with curative intent
- •Lesions identifiable only by positron emission tomography (PET)
- •Prior treatment with poly (ADP-ribose) polymerase (PARP) inhibitors, including BSI-201
- •Major medical conditions that might affect study participation (i.e., uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection)
- •Other significant co-morbid condition which the investigator feels might compromise effective and safe participation in the study, including a history of congestive cardiac failure or an electrocardiogram (ECG) suggesting significant conduction defect or myocardial ischemia
- •Enrollment in another investigational device or drug study, or current treatment with other investigational agents
- •Concurrent radiation therapy to treat primary disease throughout the course of the study
- •Inability to comply with the requirements of the study
- •Pregnancy or lactation
- •Leptomeningeal disease or brain metastases requiring steroids or other therapeutic intervention
研究组 & 干预措施
BSI-201
Experimental
BSI-201 in combination with gemcitabine and carboplatin.
干预措施: BSI-201 (Drug)
结局指标
主要结局
To evaluate the objective response rate (ORR) of gemcitabine/carboplatin in combination with BSI-201
时间窗: Until progressive disease or death
次要结局
- To determine the nature and degree of toxicity of gemcitabine/carboplatin in combination with BSI-201(30 days after last BSI-201 exposure)
- To evaluate progression-free survival (PFS) of gemcitabine/carboplatin in combination with BSI-201(until progressive disease or death)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian CancerOvarian CancerNCT01033292Sanofi43
Unknown
2 期
Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic CancerMetastatic Pancreatic CancerNCT04498689Fudan University117
终止
2 期
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p DeletionB-cell Chronic Lymphocytic Leukemia (CLL) With 17p DeletionNCT02044822Gilead Sciences102
终止
2 期
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic LymphomaSmall Lymphocytic LymphomaFollicular LymphomaNCT02258529Gilead Sciences10
已完成
2 期
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaMelanomaNCT00289640Bristol-Myers Squibb210